SpeeDx Receives CE-IVD Mark for PlexPCR® SARS-CoV-2
SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its Plex PCR ® SARS-CoV-2* assay – a two gene test for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. The high-throughput test is compatible with 96- or 384-well qPCR systems and liquid handling robotics to support a streamlined laboratory workflow and accelerate time to result.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210426005269/en/
The PlexPCR® SARS-CoV-2 assay targets two highly conserved regions of the SARS-CoV-2 genome. Designed and tested against a database of over 1,000,000 sequences, the performance of the PlexPCR® SARS-CoV-2 assay can detect all known circulating variants. The high-throughput test is compatible with 96- or 384-well qPCR systems and liquid handling robotics to support a streamlined laboratory workflow and accelerate time to result. (Photo: Business Wire)
“The COVID-19 pandemic has impacted testing laboratories throughout the world as many diagnostic supply companies have struggled to meet testing needs,” said SpeeDx CEO Colin Denver. “This has disrupted supply chains and impacted efficiency across the board. SpeeDx has the advantage of not needing to manufacture target-specific, expensive, and time-consuming testing probes. Our unique technology has allowed us to bulk produce and stockpile universal raw materials, so we are able to rapidly fulfill all our current customers’ orders while having the capacity to supply many more large-volume testing laboratories.”
The Plex PCR® SARS-CoV-2 assay targets two highly conserved regions of the SARS-CoV-2 genome (RdRp and ORF1ab). Designed and tested against a database of over 1,000,000 sequences, the performance of the Plex PCR® SARS-CoV-2 assay can detect all known circulating variants§. Regular computer-based analysis is performed to ensure new, emerging variants of the SARS-CoV-2 virus can be effectively detected, without the need for confirmatory testing.
The Plex PCR® SARS-CoV-2 assay has compatible workflow with the Plex PCR® RespiVirus† test, a two-well multiplex assay for the detection of 14 targets from 11 viral respiratory-illness causing pathogens including Influenza A, Influenza B, and Respiratory Syncytial Viruses (A & B). Both respiratory tests are also compatible with the SpeeDx Plex Prep™ - a compact and cost-effective liquid handling system. The combination of Plex Prep™ robotics and automated software analysis can support a scalable workflow for throughputs of 480 to 1,920 patient samples in an 8-hour shift. A respiratory bacteria test is due for launch later this year to complete SpeeDx’s respiratory infectious disease test portfolio.
The addition of Plex PCR® SARS-CoV-2 broadens SpeeDx’s available testing menu from the current suite of tests for sexually transmitted infections and antimicrobial resistance markers that include Resistance Plus ® MG† and Resistance Plus ® GC† – supporting Resistance Guided Therapy for Mycoplasma genitalium and gonorrhoea respectively – and Plex PCR® VHS†, a multiplex lesion diagnostic test.
*not available in the U.S. or Australia
§based on in silico investigation as of April 2021
†not available in the U.S.
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. SpeeDx has a portfolio of CE-IVD kits for detection of infectious disease pathogens, sexually transmitted infection (STI), and antimicrobial resistance markers. SpeeDx ResistancePlus tests enable Resistance Guided Therapy, improving patient outcomes by empowering practitioners to make informed clinical decisions.
For more information about SpeeDx please see: http://plexpcr.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005269/en/
Contact information
Global Marketing Director
Madeline O’Donoghue
madelineo@speedx.com.au
+61 406 582 808
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Clinical Study Publication Validates Respiratory Outcomes for the Onera Home-polysomnography System12.1.2026 15:30:00 EET | Press release
Onera Health, a leader in transforming sleep medicine, announces the recent publication of a multicenter validation study of its Onera Sleep Test System (STS) in the ERJ Open Research, a leading, fully open-access scientific journal published by the European Respiratory Society (ERS). This is the second publication from this study, and it demonstrates that the patch-based Onera STS home-polysomnography (hPSG) device accurately identifies respiratory events and distinguishes AHI severity when validated against simultaneous in-lab polysomnography and is a viable option for unattended home use. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112821647/en/ Patient sleeps with the patient-applied Onera home Polysomnography (Onera hPSG) solution. The international multicenter study was managed by an independent Clinical Research Organization and involved the analysis of 206 participants across seven clinical sites in Germany and
Riskified Analysis Reveals 1 in 4 Refund Dollars Is Abusive; Introduces "Dynamic Returns," a New Policy Protect Feature, to Safeguard Revenue While Increasing Customer Satisfaction12.1.2026 15:00:00 EET | Press release
Riskified (NYSE: RSKD) a leader in ecommerce fraud and risk intelligence, today released a research analysis highlighting a growing customer experience dilemma: As merchants tighten controls to fight a surge in return and refund abuse, they are inadvertently creating a more restrictive and frustrating experience for their best customers. To help retailers mitigate this challenge, Riskified has introduced a new feature in its Policy Protect solution, Dynamic Returns, AI-powered return decisions that adapt in real-time based on customer eligibility. Riskified's 2024 analysis of over a million refund claims found that 1-2% of total order value measured in sales dollars was requested back as refunds, with nearly 1 in 4 dollars claimed being abusive. In response to rising abuse, many retailers are implementing restrictive tactics like flat return fees, shorter return windows, and delaying refunds, often taking 10+ days for warehouse inspection. These measures frustrate good customers, as 68
BitGo Holdings Announces Launch of Initial Public Offering12.1.2026 15:00:00 EET | Press release
BitGo Holdings, Inc. (“BitGo”), the digital asset infrastructure company, today announced the launch of its initial public offering of 11,821,595 shares of Class A common stock pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (the "SEC"). The offering consists of 11,000,000 shares of Class A common stock being offered by BitGo and 821,595 shares of Class A common stock being offered by certain existing stockholders of BitGo. BitGo will not receive any proceeds from the sale of the shares by the selling stockholders in connection with the offering. In connection with the offering, BitGo intends to grant the underwriters a 30-day option to purchase up to an additional 1,770,000 shares of Class A common stock. The initial public offering price is expected to be between $15 and $17 per share. BitGo has applied to list its Class A common stock on the New York Stock Exchange under the ticker symbol "BTGO". Goldman Sachs & Co. LLC is acti
Esri’s Custom Chart Builder Adopted by the Shom (French Hydrographic and Oceanographic Office) for Nautical Chart Production12.1.2026 15:00:00 EET | Press release
Esri, the global leader in location intelligence, announced today that the Shom (French Hydrographic and Oceanographic Office) has officially adopted Custom Chart Builder (CCB) for automated production of all paper nautical charts. Following extensive testing and configuration, Shom confirmed that CCB-generated charts meet the stringent safety standards required by the French Navy, marking a pivotal advancement in automating maritime cartography and reinforcing its role as a pioneer in maritime digital transformation. “This adoption demonstrates that high-quality, regulation-compliant paper charts can now be produced without manual intervention, dramatically reducing production time and cost,” said Rafael Ponce, Esri principal maritime consultant. “Shom’s endorsement validates Esri’s CCB as a trusted solution for hydrographic offices worldwide, supporting the transition to digital-first workflows and e-navigation.” Over the course of 2024, Shom evaluated multiple software solutions and
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas12.1.2026 14:30:00 EET | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that France’s National Agency for Medicines and Health Products Safety (ANSM) has approved an updated national treatment protocol for botensilimab (BOT) plus balstilimab (BAL) under France’s Autorisation d’Accès Compassionnel (AAC) framework. The updated protocol expands France’s previously granted AAC authorization for BOT+BAL in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases to eligible patients with certain ovarian cancers and soft-tissue sarcomas—diseases with substantial unmet medical need after standard options have been exhausted. The revised protocol is designed to broaden the eligibility criteria, allowing more patients with advanced solid tumors to have early access to BOT+BAL under reimbursed compassionate use, and to enhance monitoring and treatment procedures in participating hospitals. BOT+BAL is a chemotherapy- and radiation-f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom